Potentiation of urinary atrial natriuretic peptide interferes with macula densa function.
OBJECTIVE
Neutral endopeptidase (NEP) inhibition potentiated the renal action of Atrial Natriuretic Peptide (ANP) and was associated with appearance of the peptide in the urine, providing evidence of protection of the filtrated peptide along the course of the nephron. The macula densa, composed of epithelial cells, receives ionic information from the urinary compartment via Na-K-2Cl cotransport and influences renin secretion by the myoepithelioïd cells in the afferent arteriole. bNOS constitutively expressed in the epithelial cells of the macula densa is involved in this feed-back. NEP inhibition was associated with the absence of any increase in renin secretion. The hypothesis is that potentiation of urinary ANP by NEP inhibition could limit renin secretion by directly or indirectly targeting the macula densa in vivo.


RESULTS
We tested the interaction between NEP inhibition (candoxatril) and Na-K-2Cl inhibition (bumetanide) on electrolyte and ANP urinary excretion, renin secretion, macula densa activity (NADPH diaphorase activity and bNOS mRNA) and TSC-1 mRNA expression in the renal cortex and BSC-1 in the renal medulla of rats treated for 5 days. Bumetanide increased urinary electrolyte excretion whereas candoxatril did not. Candoxatril increased urinary ANP and cyclic GMP excretion. Bumetanide increased renin and aldosterone secretion whereas candoxatril decreased renin secretion. This effect on renin release was associated with an increase in macula densa NADPH diaphorase activity in the bumetanide-treated group which was blunted by candoxatril. Lastly, bumetanide increased TSC-1 mRNA expression in the cortex and this effect was blunted by candoxatril.


CONCLUSIONS
These results suggest that potentiation of ANP by NEP inhibition could interfere with tubular function at different levels and limit renin secretion by a urinary pathway involving macula densa activity.
Haloui
M
M
U460, Centre Hospitalier Universitaire Xavier, Bichat, 75018, Paris, France
Messika-Zeitoun
D
D
Louedec
L
L
Philippe
M
M
Michel
J B
JB
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000502:physiology / Q000652:urine*; D002034:Bumetanide / Q000494:pharmacology; D002712:Chlorides / Q000652:urine; D006152:Cyclic GMP / Q000652:urine; D004231:Diuresis / Q000187:drug effects; D004847:Epithelial Cells / Q000502:physiology; D007189:Indans / Q000494:pharmacology; D007686:Kidney Tubules, Distal / Q000378:metabolism / Q000502:physiology*; D008297:Male; D009252:NADPH Dehydrogenase / Q000378:metabolism; D015260:Neprilysin / Q000037:antagonists & inhibitors; D019001:Nitric Oxide Synthase / Q000378:metabolism; D011188:Potassium / Q000652:urine; D011422:Propionates / Q000494:pharmacology; D011506:Proteins / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D012964:Sodium / Q000652:urine; D000077004:Tuberous Sclerosis Complex 1 Protein; D025521:Tumor Suppressor Proteins
D002712:Chlorides; D007189:Indans; D011422:Propionates; D011506:Proteins; D000077004:Tuberous Sclerosis Complex 1 Protein; D025521:Tumor Suppressor Proteins; D002034:Bumetanide; D009320:Atrial Natriuretic Factor; D012964:Sodium; C062766:candoxatril; D019001:Nitric Oxide Synthase; D009252:NADPH Dehydrogenase; D015260:Neprilysin; D006152:Cyclic GMP; D011188:Potassium